Therapeutic Prospects for Th-17 Cell Immune Storm Syndrome and Neurological Symptoms in COVID-19: Thiamine Efficacy and Safety, In-vitro Evidence and Pharmacokinetic Profile

Vatsalya Vatsalya, Fengyuan Li, Jane Frimodig, Khushboo S. Gala, Shweta Srivastava, Maiying Kong, Vijay A Ramchandani, Wenke Feng, Xiang Zhang, Craig J McClain
doi: https://doi.org/10.1101/2020.08.23.20177501

Abstract

Introduction Emerging infectious diseases, especially the coronavirus disease identified in 2019 (COVID-19), can be complicated by a severe exacerbation in the Th17 cell-mediated IL-17 proinflammatory immune storm. This enhanced immune response plays a major role in mortality and morbidity, including neurological symptoms. We hypothesized that countering the cytokine storm with thiamine may have therapeutic efficacy in lowering the Th17 cell proinflammatory response. We used an in vitro study and corroborated those results in disease controls (DC). We developed an effective dose range and model for key pharmacokinetic measures with the potential of targeting the cytokine storm and neurological symptoms of COVID-19.

Study Participants and Methods We investigated the effect of a three-week 200 mg dose of thiamine in lowering the Th17 response in sixteen DC (proinflammatory origin due to heavy alcohol drinking) patients; and eight healthy control/volunteers (HV) as a pilot clinical-translational investigation. To further investigate, we performed an in vitro study evaluating the effectiveness of thiamine treatment in lowering the Th17 proinflammatory response in a mouse macrophage cell line (RAW264.7) treated with ethanol. In this in vitro study, 100 mg/day equivalent (0.01 µg/ml) thiamine was used. Based on recent publications, we compared the results of the IL-17 response from our clinical and in vitro study to those found in other proinflammatory disease conditions (metabolic conditions, septic shock, viral infections and COVID-19), including symptoms, and dose ranges of effective and safe administration of thiamine. We developed a dose range and pharmacokinetic profile for thiamine as a novel intervention strategy in COVID-19 to alleviate the effects of the cytokine storm and neurological symptoms.

Results The DC group showed significantly elevated proinflammatory cytokines compared to HV. Three-week of 200 mg daily thiamine treatment significantly lowered the baseline IL-17 levels while increased IL-22 levels (anti-inflammatory response). This was validated by an in vitro macrophage response using a lower thiamine dose equivalent (100 mg), which resulted in attenuation of IL-17 and elevation of IL-22 at the mRNA level compared to the ethanol-only treated group. In humans, a range of 79-474 mg daily of thiamine was estimated to be effective and safe as an intervention for the COVID-19 cytokine storm. A literature review showed that several neurological symptoms of COVID-19 (which exist in 45.5% of the severe cases) occur in other viral infections and neuroinflammatory states that may also respond to thiamine treatment.

Discussion The Th17 mediated IL-17 proinflammatory response can potentially be attenuated by thiamine. Thiamine, a very safe drug even at very high doses, could be repurposed for treating the cytokine/immune storm of COVID-19 and the subsequent neurological symptoms observed in COVID-19 patients. Further studies using thiamine as an interventional/prevention strategy in severe COVID-19 patients could identify its precise anti-inflammatory role.

Introduction

Viral diseases and wide-spread outbreaks have adverse health-related consequences worldwide. Emerging infectious diseases (EID) include viral pathogens that have shown higher incidence of human infection in the past several decades and raise concerns regarding increased ongoing/future prevalence1. Coronavirus is recognized as an EID that has become a challenging and aggressive infection with high morbidity and mortality in humans2. SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2; causes coronavirus disease [COVID-19]) was identified in 2019, has become a pandemic, and is a priority healthcare concern in the year 20203.

In viral infections, tissue inflammation is driven by multiple proinflammatory and immunoregulatory signals4,5. The pathological progression of COVID-19 has multiple clinical stages and may present with the cytokine storm syndrome6 and immunosuppression7. Interleukin-17 (IL-17) is a cytokine8 that is often involved in a proinflammatory response in the cytokine storm of viral infections9–11. It can also promote respiratory viral infections12, tissue pathology13–15, and neurological manifestations16. Th17 cells also produce Interleukin-22 (IL-22), which plays a protective/anti-inflammatory role, and it is dysregulated in several proinflammatory conditions17. Thus, a therapy that could alleviate the Th17 mediated pro-inflammatory response18 might be effective in attenuating the cytokine storm observed in COVID-19 patients.

Thiamine, a vitamin and dietary supplement,19 has anti-oxidant properties19,20. High levels of cytokines (for example, IL-1β and IL-6) may occur in thiamine deficient subjects and can be associated with oxidative stress and inflammation21,22. Importantly, thiamine administration could inhibit production of these cytokines, increase anti-inflammatory activity23,24, and potentially alleviate neuroinflammatory symptoms of viral origin25,26.

We tested the efficacy of a three-week thiamine treatment in modulating the Th17 proinflammatory response in a human disease control model of conditions associated with inflammation. To validate the effectiveness of thiamine in treating the proinflammatory response from the human study, we conducted an in vitro experiment to test the effects of thiamine treatment in alleviating ethanol mediated immune dysregulation in a mouse macrophage cell line, RAW264.7. We investigated the Th17 cells proinflammatory cytokine response (namely IL-17) in both healthy controls and individuals with high inflammatory response. This was done to estimate the effects of various doses of thiamine that have shown efficacy in alleviating the Th17 associated cytokine response. We assessed the pharmacokinetics of the oral thiamine dosing. Lastly, we also examined the neurological symptoms of COVID-19 that could possibly be treated with thiamine.

Study Participants and Methods

Study Participants

This investigation was approved under two large clinical investigations that were conducted at the University of Louisville (NCT#01809132, HV cohort), and the National Institute on Alcohol Abuse and Alcoholism (NIAAA) (NCT#00106106, DC cohort) at the National Institutes of Health (NIH), Bethesda MD. The studies were approved by the NIH Institutional Review Board (IRB) committee and the UofL IRB (IRB # 12.0427). All DC (disease controls as termed in this study, who were alcohol use disorder [AUD]) patients received acamprosate (or placebo) as part of a larger addiction intervention investigation. All of these patients also received thiamine as part of the medical management, which is the primary aim of this study. Sixteen age- and sex- matched male and female alcohol use disorder (AUD) patients (Termed as disease controls [DC] in this investigation) between 21-65 yrs. of age with both present and past heavy drinking profile participated as the DC, who were diagnosed with AUD based on DSM-IV TR criteria. They received daily doses of open label thiamine (100 mg twice daily = 200 mg per day)27 for 3-weeks after completion of the consenting process. DC patients also received standard of care inpatient medical management, including counseling. Detailed information on subject recruitment and management can be obtained from several of our previous publications28–31. We also included eight healthy controls in this study for comparison with DC. Demographic data were collected from all the participants. Baseline (HV and DC) and post-treatment (DC only) blood samples (after the completion of 3-weeks of thiamine dosing) were collected, processed (for plasma extraction) and frozen at −80°C. They were subsequently thawed and assayed. Laboratory Assays and Therapeutic Model on Th17 Inflammation Axis

(1) Cytokine assays

Plasma levels of proinflammatory cytokines, IL-1β, IL-6, and IL-10 were obtained by multianalyte chemiluminescent detection using Multiplex kits (Millipore, Billerica, MA) on the Luminex platform (Luminex, Austin, TX), according to manufacturers’ instructions.

(2) Analysis of IL-17 and IL-22 in a set of AUD patients for designing proof-of-concept experimental model

We performed analyses for IL-17 and IL-22 on human plasma samples to estimate the Th17 inflammatory response, with the goal of developing an in vitro mechanistic experimental model to test the efficacy of thiamine. The plasma levels of IL-17 and IL-22 in eight healthy volunteers were also included in this study for comparison. IL-17 and IL-22 were detected in plasma using Human IL-17A (now called IL-17) High Sensitivity ELISA Kits (BMS2017HS, Invitrogen) and Human IL-22 ELISA Kits (BMS2047, Invitrogen) per the manufacturer’s instructions. Results were read on a Spectra Max Plus 384 plate reader and modeled using their SoftMax Pro software (Molecular Devices, San Jose, CA).

(3) Cell culture

RAW 264.7 cells (mouse macrophage cell line) were cultured in Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen), supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. Cells were seeded in a 24-well culture plate and maintained at 37 °C in a 5% CO2 incubator for 3 days. The 0.02 µg/mL treatment dose was equivalent to the 200 mg/day thiamine dose (approximate blood AUC = 204 nmol/L32) given to the patients. Cells were then treated with thiamine (Vit B1 [VB1] as shown in the Figure 2) at a concentration of (0.01 µg/mL) for 2 hours (in a preventive paradigm), followed by 80 mM ethanol treatment for 22 hours, for a total of 24 hours of treatment to determine the minimum effective level of thiamine to reduce the Th17 response. Cells were then washed with PBS and collected with Trizol reagent for the isolation of RNA. RNA samples were reverse transcribed to cDNA and used for qRT PCR analysis of cytokine expression (IL-17, IL-22). Cell viability was not affected by thiamine or EtOH treatment at the doses used in the experiments.

Figure 1:
Figure 1:

Efficacy of thiamine treatment on Th17 cell derived response for IL-17, and IL-22 cytokines. Levels of IL-17 and IL-22 in healthy volunteers (HV) at baseline; and Disease Controls (DC or [alcohol use disorder, AUD]) patients exhibiting a proinflammatory response (n = 16) at baseline; and anti-inflammatory normalization of cytokines tested after the completion of three-week (W3) thiamine treatment. A drop in IL-17 coupled with a mild increase in IL-22 at W3 was observed compared to the baseline levels. BL: baseline, W3: three-week of thiamine treatment. Data are presented as M±SD. Statistical significance was set as p < 0.05.

Figure 2:
Figure 2:

mRNA expression of IL-17 and IL-22 in an in vitro model of the mouse macrophage cell line using a potent proinflammatory agent (alcohol), and preventative administration of thiamine. Fig. 2a: Significant lowering was observed in IL-17 mRNA expression in “EtOH + VB1” (Bar 4) group compared to the alcohol-treated group (Bar 3). Fig. 2b: Significant elevation was observed in IL-22 mRNA expression in “EtOH + VB1” (Bar 4) group compared to the alcohol-treated group (Bar 3). Controls (both Fig. 2a and 2b) show normal anti-inflammatory effects of thiamine on IL-17 and IL-22 response with thiamine administration. Ctrl: Non-treated controls. VB1 0.01 ug/ml. EtOH: alcohol treated. VB1+E: thiamine and alcohol treated. Data are presented as M±SD. Statistical significance was set as p < 0.05.

(4) RNA isolation and real-time RT-PCR

Total RNA was extracted from the cells using Trizol reagent (500 µl/well) according to manufacturer’s instruction (Life Technologies, Carlsbad, CA) and reverse-transcribed using cDNA Supermix (QuantaBio, Beverly, MA). Quantitative real-time PCR was performed on an ABI 7500 real-time PCR thermocycler and SYBR green PCR Master Mix (Applied Biosystems, Foster City, CA) was used for quantitative real-time PCR analysis. The relative quantities of target transcripts were calculated from duplicate samples after normalization of the data against the housekeeping gene, mouse 18S. Relative mRNA expression was calculated using comparative Ct method. The following primer pairs were used:

Development of the Pharmacokinetic Model for Dose Titration of Thiamine

We used dosing guidelines for thiamine as mentioned at the Medline Plus (https://medlineplus.gov/druginfo/natural/965.html#Safety, last reviewed as of August 5, 2020), and from peer reviewed publications from PubMed (https://pubmed.ncbi.nlm.nih.gov/; [searched and collected until August 5, 2020]). We used available dosing guidelines from Medline Plus for healthy individuals both for dietary supplementation and vitamin deficiency status. We also reviewed and incorporated thiamine dose levels (lower and higher range) from other disease conditions; namely metabolic conditions33,34, septic shock35,36, viral diseases37–39 and Leigh’s disease40 (Medline Plus: Thiamine). We also included the recorded thiamine dose levels from the DC group (AUD with Wernicke Korsakoff Syndrome, WKS41; from our clinical study) as one of the pro-inflammatory conditions.

We compared the reference range of levels of the Th17 cytokine (IL-17) response in disease/health conditions in humans as published in the recent findings concerning COVID-19’s cytokine storm data42–44. A Th17 proinflammatory response for the potential range of IL-17 levels was also developed for healthy volunteers (HV, from our study cohort), metabolic conditions45,46, DC (or alcohol use disorder patients from our study cohort), septic shock47,48, and viral infections12,49. IL-17 data on severe COVID-19 patients (as mentioned above) were collected from the recently peer-reviewed published articles found in PubMed (searched until August 5, 2020). Doses administered to our DC study cohort, and data from healthy individuals (HV) were also used in the development of the dose profile. All these data were incorporated in the predictive regression model for identifying a tentative effective dose range of thiamine (Figure 3).

The pharmacokinetic response of thiamine was calculated at both the low and high ends of the dose range described above. The area under the curve and maximum concentration (Cmax) were established for both blood and plasma for a 10-hour trajectory (Figure 4) using the indices of thiamine’s in vivo blood pharmacokinetics32. For the derived 79 mg thiamine dosing (low end), the slopes used to identify AUC in blood were 2.14, and 1.76 in plasma. For the 474 mg thiamine dosing (upper end), the slope used to derive AUC in blood was 1.02, while in plasma it was 1.09. Similarly, for the 79 mg thiamine dosing, the slope used to derive Cmax in blood was 0.40, and in plasma it was 0.39. For the 474 mg thiamine dose, the slope used to derive AUC in blood was 0.14, and in plasma it was 0.18.

Statistical Analysis

Data are expressed as Mean ± standard deviation (M±SD) in Table 1 as well as in Figures 1 and 2. Two-sided Student’s t-test was used to examine the difference between disease controls and healthy volunteers at baseline (see Suppl. Table 1 and Fig. 1), and two-sided Student’s paired t-test was used to examine the changes at baseline versus 3 weeks for disease controls (Figure 1).

View this table:
Table 1.

Neurological symptoms in COVID-19, Viral Encephalitis (Grouped/assorted by the neurological spectrum observed in COVID-19), showing their proximity in presentation. Therapeutic effects of thiamine on the corresponding neurological symptoms of pro-inflammatory origin that are also observed in viral infection.

Post-hoc one-sided t-tests were performed for the IL-17 and IL-22 mRNA expression analyses for the RAW 264.7 cells testing (Figure 2). A pharmacokinetic model for anticipated therapeutic dosing range of thiamine based on IL-17 ranges in different inflammatory conditions was constructed using predictive regression computation (Figure 3). Factorial between-group ANOVA was used to evaluate demographic and cytokine profiles (Table 1). Statistical significance was established at p < 0.05. SPSS 26.0 (IBM Chicago, IL) and Microsoft Excel 365 (MS Corp, Redmond WA), statistical software R (https://www.r-project.org/), and Prism GraphPad (GraphPad Software, San Diego CA) were used for statistical analysis, data computation, and plotting the figures.

Figure 3:
Figure 3:

PRIMARY: A dose titration by disease and proinflammatory Th17 status model of thiamine administration with parallel representation of Th17 proinflammatory response in various groups including healthy volunteers and disease groups with pro-inflammatory response. Fig. 3A: Linear regression model is predictive for the relation between the low dose thiamine (Vit B1) range versus low IL-17 ranges based on known observed pairs from different patients; lower range of vit B1 dose (79 mg/daily) corresponding to lower range of IL-17 (15 ng/ml) in the COVID-19 patients. Dark grey shade depicts higher IL-17 response and lighter grey shade shows lower IL-17 response in various proinflammatory conditions. Fig. 3B: Linear regression shows the predictive model for the relation between a higher range of Vit B1 dose versus a higher range of IL-17 levels, derived from the known observed pairs from different patients; higher range of Vit B1 dose (474 mg/daily) corresponding to higher range of IL-17 (40 ng/ml) reported in COVID-19 patients. High Range Thiamine Dose: Left Y-axis (primary). Low Range Thiamine Dose, Low Range IL-17 levels, and High range IL-17 levels: Right Y-axis (Secondary).

Neurological Assessments

We conducted a review on the neurological presentation in COVID-19 and other relevant viral occurrences of encephalitis (Table 1). We identified and tabulated the neurological symptoms of COVID-19 and viral encephalitis from the recently published findings. We also described the neurological symptoms, that are generally treated effectively with thiamine (Table 1). We used PubMed and Medline Plus for disease references (searched until August 5, 2020).

Results

Demographics and Candidate Proinflammatory Cytokine Profile

DC group individuals in this study had significantly higher age than the healthy controls (HV) (Suppl Table 1). However, there was no significant difference in the mean BMIs between the two groups, and the sex-distribution was also similar between the two groups. Both IL-6 (∼6 fold) and IL-1β (∼3 fold) cytokines were significantly higher in the DC group (AUD patients) compared to the healthy controls/volunteers (HV) group. IL-10 was also numerically higher in the DC group.

Clinical Findings on the Immune Response of Th17 derived IL-17 and IL-22 Axis Response, and Thiamine Efficacy and Safety

To develop a model for thiamine effects on inflammation, we assessed IL-17 and IL-22 cytokine expression (showing proinflammatory and anti-inflammatory effects, respectively). Both cytokines are produced by the Th17 cells50. IL-17 concentrations were below the level of detection in the HV group, but were elevated in the DC group. An approximate four-fold decrease was observed in the IL-17 concentration levels (0.09 pg/mL to 0.023 pg/mL) with a treatment dose of 200 mg thiamine daily (Estimated AUC = 204 nmol/L × hour approximately in the 10-hr. window) by the end of week 3. IL-22 was significantly decreased in DC group compared to healthy volunteers and thiamine therapy did not significantly improve levels in treated DC group individuals. No patients reported any kind of drug related adverse events; therefore, the safety profile of thiamine administration was excellent at 200 mg daily in this small pilot group.

Experimental Model for Treatment Efficacy of Thiamine on IL-17 and IL-22 Activity

Using these clinical findings of the treatment efficacy of thiamine, we designed an in vitro experiment using mouse macrophage RAW264.7 cells to validate the effects of thiamine on alcohol-induced IL-17 and IL-22 expression. The results showed that a low dose of thiamine (VB1) decreased IL-17 expression in the absence (by 20% approximately) and/or presence of alcohol treatment (by 25% roughly) (Figure 2a). Importantly, IL-22 expression was upregulated by thiamine in both the control and ethanol-treated cells. This response in IL-22 expression was moderately reduced by alcohol but rescued by the thiamine (VB1) treatment (Figure 2b). Half of the treatment dose (0.02 µg/mL) that was found to be effective in humans was beneficial as a preventative dose (0.01 µg/mL) of thiamine in this in vitro model.

IL-17 Dependent Dose and Pharmacokinetic Model of Thiamine

An IL-17 response dependent dose and pharmacokinetic model of thiamine administration was developed, based on responses from the pro-inflammatory disease cohorts and the corresponding thiamine dosing (controlled for by the corresponding values in healthy volunteers, as a point of reference). This model supported a tentative range of thiamine dosing for COVID-19 (Figures 3A and 3B), since the IL-17 levels are much higher in COVID-19 than in the reports from many other proinflammatory disease conditions. Using regression analysis, a range of 79 mg/day (lower end of dose range) - 474 mg/day (higher end of dose range) for thiamine administration was found to correspond to a range of 15-40 ng/mL level of IL-17 used in vitro.

The pharmacokinetic parameters were: Area Under the Curve (AUC), and Maximum (or peak) Concentration of a drug (Cmax). These gave a very close estimation of the specific oral thiamine dose (Figure 4). As expected, plasma values were higher for both AUC and Cmax at higher doses and were lower at lower doses (Suppl Table 2).

Figure 4:
Figure 4:

Pharmacokinetics parameters of oral thiamine over 10 hr. (Projected) in whole blood and plasma. Fig. 4a: Predicted course of Area Under the Curve (AUC) for low values (79 mg/day) and high values (474 mg/day) of the range of oral thiamine dose in blood and plasma over the 10 hours. Fig. 4b: Predicted maximum concentration of low values (79 mg/day) and high values (474 mg/day) of the range of oral thiamine dose in blood and plasma over the first 10 hours. Errors bars show a 5% variability in the pharmacokinetic measures at each dose.

Assessment of Neurological Presentation of COVID-19, Viral Encephalitis and Therapeutic Efficacy of Thiamine Administration

We tabulated the neurological symptoms from the recently published findings on COVID-19 (Table 1). Severely ill COVID-19 patients presented with various neurologic symptoms that could be grouped together as: acute cerebrovascular disease; altered mental status; and musculoskeletal symptoms51. We also included the neurological presentation commonly observed in viral encephalitis of non-COVID-19 origin, grouped corresponding to the presentation of the symptoms of COVID-19.

Lastly, we also tabulated the neurological symptoms that are commonly treated with thiamine. Several neurological symptoms of COVID-19 and viral encephalitis corresponded well with the neurological spectrum that is known to be managed effectively with thiamine.

Discussion

We evaluated individuals with significantly altered IL-17 and IL-22 responses associated with Th17 cells and found a significant role for a 3-week 200 mg/daily thiamine treatment regimen in improving the Th17 response in the AUD disease control patient cohort whose members exhibited a high pro-inflammatory status at baseline. SARS CoV-2 viral challenge causes induction of IL-6 leading to altered Th17 responses52. IL-17 synthesized by Th17 cells can markedly stimulate neutrophil chemotaxis and may lead to a skewed Th2 immune response53,54. Results from our AUD control group show the increases in candidate proinflammatory (IL-1β and IL-17), and anti-inflammatory (IL-6, IL-10 and IL-22) cytokines. Changes in IL-17 and IL-22 with alcohol abuse (pro-inflammatory), and thiamine as an anti-inflammatory therapy in our experiment provided potential proof of concept. IL-1β is a key cytokine initiating Th17 cells to synthesize IL-1755, whereas IL-10 suppresses Th17 proinflammatory cytokine production56. High IL-6 levels also are associated with Th17 cell proinflammatory activity52. Thus, under inflammatory conditions, there is a complex interaction of proinflammatory/anti-inflammatory responses from Th17 cells. An intervention or prevention that could attenuate the Th17 proinflammatory activity could help ameliorate the consequences of a cytokine storm.

Thiamine deficiency has been reported to promote a proinflammatory response in Th1 and Th17 cells57. To examine the role of thiamine in treating inflammation, in vitro testing was used to mechanistically examine the clinical outcomes. Our in vitro model showed that thiamine could effectively lower IL-17 and increase IL-22 mRNA expression in macrophages. Both our clinical data, and the in vitro studies suggest that thiamine could play a potential role in attenuating the cytokine storm in patients who have a strong proinflammatory response.

A study using a mouse model showed that IL-17 augments respiratory syncytial virus (RSV)-induced lung inflammation58. In that study, immunodepletion of IL-17 before viral infection resulted in diminished RSV-driven mucous cell hyperplasia and airspace enlargement, suggesting IL-17 as a potential therapeutic target. Proinflammatory IL-17 production could also initiate pulmonary eosinophilic response, by promoting proliferation of eosinophils in the bone marrow, followed by recruitment and extravasation into the lungs59. These recent findings suggest that suppression of IL-17 may be vital to managing viral infections, including COVID-19 and their harmful consequences.

We derived an effective dose range of thiamine that could be administered for alleviating the Th17 cell proinflammatory response by using the IL-17 concentrations that we obtained from our AUD patients (termed as DC), levels found in the literature, and levels in the healthy control (HV) group. Thiamine has been administered as a treatment in other viral infections60,61, and has proven effective for some inflammatory conditions and symptoms62,63. A well-structured treatment profile of thiamine based on the results of proof of concept in vitro experiments, and analyses of proinflammatory response-relevant disease conditions support the potential efficacy of thiamine in ameliorating the proinflammatory Th17 response in severe COVID-19 patients. Use of preventive as well as interventional dosages show potential in the management of COVID-19. Thiamine Ctrough is reached generally in 10-12 hours; thus, the total dose prescribed can be divided into two doses per day. This may lead to fewer AEs or other side effects.

One recent report identified that 36.4% of the COVID-19 diagnosed patients have neurologic symptoms, and this proportion was higher (45.5%) among those COVID-19 patients with more severe symptoms51. Patients with other viral diseases have also shown clinical symptoms of beriberi64, or Wernicke-Korsakoff syndrome (autopsies of 380 people with AIDS showed Wernicke’s encephalopathy in 10% of the cases)65, and these conditions are associated with thiamine deficiency. It is possible that patients with viral infection could have an increased risk of thiamine deficiency, but this information has remained largely unexplained in viral diseases66, including COVID-19. A potential reason could be that a deficiency in thiamine could be related to the thiamine transport protein, which can have a general preference for multiple membrane transport molecules which can function as receptors for candidate viruses67. The Th17 proinflammatory response has also been reported in the experimental encephalomyelitis model57. Thus, thiamine could be a therapeutic agent to alleviate neurological symptoms of COVID-19.

Adverse effects (AE) of thiamine are minimal and generally mild. Possible AEs include nausea, diarrhea, and abdominal pain. Rarely, individuals also suffer serious allergic reactions. There is no reported drug related symptoms at the 200 mg thiamine dose used in our study, and there are no reported AEs. A landmark pharmacokinetic study utilizing a 1500 mg maximum oral dose of thiamine in healthy subjects showed rapid absorption32. Moreover, 4000 mg thiamine administration showed no to mild AEs when used in children (Leigh’s disease). Thus, higher doses of thiamine for treatment of COVID-19’s cytokine storm could be considered a safe therapy.

Our study has several limitations. This is a small study. However, both clinical and in vitro evidence collectively support the potential of thiamine as a therapeutic agent in attenuating the Th17 proinflammatory response. We did not test the in vitro/in vivo efficacy of thiamine in the treatment of COVID-19 or its derivative stimulated Th17 proinflammatory response directly. We anticipate conducting such in vitro experiments for COVID-19 as a continuation of this project. Moreover, plasma thiamine levels have not been assessed in COVID-19. Our study did not have sufficiently large numbers of males and females; thus, identifying sex-differences was not within the scope of this study.

In summary, Thiamine has been approved by the Food and Drug Administration (FDA) of the USA as a prescription product and is considered very safe even at higher doses since it is water soluble and can be excreted via urine, if in excess68. Given its robust safety record, we suggest that thiamine should be considered for COVID-19 treatment studies.

Data Availability

The datasets analyzed during the current study are available from the corresponding author by request.

Ethics approval and consent to participate

Study was approved by the sites’ Institutional Review Boards (Ethics committees). All patients included in this study consented to participate before the beginning of the study.

Availability of data and materials

The datasets analyzed during the current study are available from the corresponding author by request.

Disclosure

This article is not published nor is under consideration for publication elsewhere at the time of submission.

Trial registration

https://ClinicalTrials.gov identifier – NCT# 01809132 and 00106106.

Reprint requests

Vatsalya Vatsalya MD, PgD, MSc, MS, Department of Medicine, University of Louisville School of Medicine, 505 S. Hancock St., CTR Room 514A, Louisville KY 40202 USA. Tel.: 502-852-8928. Fax: 502-852-8927. E-mail: v0vats01{at}louisville.edu.

Acknowledgments

We thank research/clinical staff of the University of Louisville for their support. We thank Ms. Marion McClain for editing this manuscript.

Footnotes

  • Conflicts of Interest: All authors declare no conflict of interests.

  • Proprietorship: This article is a work of the University of Louisville Alcohol Research Center and National Institutes of Health. This manuscript is in the public domain in the USA. Email address for the readers to contact the author to obtain the data: v0vats01{at}louisville.edu.

  • Project/Grant Support: Study was supported by NIH: NIH-OD-OHSRP-12176 (VV), R15CA170091-01A1 (MK), ZIA AA000466 (VAR), R01AA023190 (WF), P50AA024337-8301 and P20GM113226-6169 (XZ), and P50AA024337, P20GM113226, U01AA026936, U01AA0279880, R01AA023681 (CJM). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Abbreviations

COVID-19
Coronavirus Disease-19
IL-17
Interleukin 17
IL-22
Interleukin 22
Disease Controls
(DC)
HV
Healthy Volunteers

References

  1. 1.↵
    Hassell JM, Begon M, Ward MJ, Fèvre EM. Urbanization and disease emergence: dynamics at the wildlife–livestock–human interface. Trends in ecology & evolution. 2017;32(1):55–67.
    OpenUrl
  2. 2.↵
    Poon LL, Peiris M. Emergence of a novel human coronavirus threatening human health. Nature medicine. 2020;26(3):317–319.
    OpenUrl
  3. 3.↵
    HuiDS IAE, Madani T, Ntoumi F, Koch R, Dar O. The continuing 2019-nCoV epidemicthreatof novel coronaviruses to global health: the latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis. 2020;91:264–266.
    OpenUrlCrossRefPubMed
  4. 4.↵
    Glass WG, Rosenberg HF, Murphy PM. Chemokine regulation of inflammation during acute viral infection. Current opinion in allergy and clinical immunology. 2003;3(6):467–473.
    OpenUrlCrossRefPubMed
  5. 5.↵
    Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LF. The trinity of COVID-19: immunity, inflammation and intervention. Nature Reviews Immunology. 2020:1–12.
  6. 6.↵
    Pedersen SF, Ho Y-C. SARS-CoV-2: a storm is raging. The Journal of clinical investigation. 2020;130(5).
  7. 7.↵
    Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet. 2020;395(10229):1033–1034.
    OpenUrlCrossRef
  8. 8.↵
    Aggarwal S, Gurney AL. IL-17: prototype member of an emerging cytokine family. Journal of leukocyte biology. 2002;71(1):1–8.
    OpenUrlPubMedWeb of Science
  9. 9.↵
    Reed M, Morris SH, Owczarczyk AB, Lukacs NW. Deficiency of autophagy protein Map1-LC3b mediates IL-17-dependent lung pathology during respiratory viral infection via ER stress-associated IL-1. Mucosal immunology. 2015;8(5):1118–1130.
    OpenUrl
  10. 10.
    Jain A, Pandey N, Garg R, Kumar R. IL-17 level in patients with Dengue virus infection & its association with severity of illness. Journal of clinical immunology. 2013;33(3):613–618.
    OpenUrl
  11. 11.↵
    Yuan J, Yu M, Lin Q-W, et al. Neutralization of IL-17 inhibits the production of anti-ANT autoantibodies in CVB3-induced acute viral myocarditis. International immunopharmacology. 2010;10(3):272–276.
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    Mukherjee S, Lindell DM, Berlin AA, et al. IL-17–induced pulmonary pathogenesis during respiratory viral infection and exacerbation of allergic disease. The American journal of pathology. 2011;179(1):248–258.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    Du W-J, Zhen J-H, Zeng Z-Q, et al. Expression of interleukin-17 associated with disease progression and liver fibrosis with hepatitis B virus infection: IL-17 in HBV infection. Diagnostic pathology. 2013;8(1):40.
    OpenUrl
  14. 14.
    Li C, Yang P, Sun Y, et al. IL-17 response mediates acute lung injury induced by the 2009 pandemic influenza A (H1N1) virus. Cell research. 2012;22(3):528–538.
    OpenUrlCrossRefPubMed
  15. 15.↵
    Klatt NR, Estes JD, Sun X, et al. Loss of mucosal CD103+ DCs and IL-17+ and IL-22+ lymphocytes is associated with mucosal damage in SIV infection. Mucosal immunology. 2012;5(6):646–657.
    OpenUrl
  16. 16.↵
    Ye M, Ren Y, Lv T. Encephalitis as a clinical manifestation of COVID-19. Brain, behavior, and immunity. 2020.
  17. 17.↵
    Eyerich K, Dimartino V, Cavani A. IL-17 and IL-22 in immunity: Driving protection and pathology. European journal of immunology. 2017;47(4):607–614.
    OpenUrlCrossRefPubMed
  18. 18.↵
    Pacha O, Sallman MA, Evans SE. COVID-19: a case for inhibiting IL-17? Nature Reviews Immunology. 2020;20(6):345–346.
    OpenUrlPubMed
  19. 19.↵
    Cooper JR, Pincus JH. The role of thiamine in nervous tissue. Neurochemical research. 1979;4(2):223–239.
    OpenUrlCrossRefPubMedWeb of Science
  20. 20.↵
    Thornalley PJ. The potential role of thiamine (vitamin B1) in diabetic complications. Current diabetes reviews. 2005;1(3):287–298.
    OpenUrl
  21. 21.↵
    Neri M, Cantatore S, Pomara C, et al. Immunohistochemical expression of proinflammatory cytokines IL-1β, IL-6, TNF-α and involvement of COX-2, quantitatively confirmed by Western blot analysis, in Wernicke’s encephalopathy. Pathology-Research and Practice. 2011;207(10):652–658.
    OpenUrl
  22. 22.↵
    de Andrade JAA, Gayer CRM, de Almeida Nogueira NP, et al. The effect of thiamine deficiency on inflammation, oxidative stress and cellular migration in an experimental model of sepsis. Journal of Inflammation. 2014;11(1):11.
    OpenUrl
  23. 23.↵
    Menezes RR, Godin AM, Rodrigues FF, et al. Thiamine and riboflavin inhibit production of cytokines and increase the anti-inflammatory activity of a corticosteroid in a chronic model of inflammation induced by complete Freund’s adjuvant. Pharmacological Reports. 2017;69(5):1036–1043.
    OpenUrl
  24. 24.↵
    Shahmiri FA, Soares M, Zhao Y, Sherriff J. High-dose thiamine supplementation improves glucose tolerance in hyperglycemic individuals: a randomized, double-blind cross-over trial. European journal of nutrition. 2013;52(7):1821–1824.
    OpenUrlCrossRefPubMed
  25. 25.↵
    Protheroe S, Mellor D. Imaging in influenza A encephalitis. Archives of disease in childhood. 1991;66(6):702–705.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    Brechtelsbauer D, Urbach H, Sommer T, Blümcke I, Woitas R, Solymosi L. Cytomegalovirus encephalitis and primary cerebral lymphoma mimicking Wernicke’s encephalopathy. Neuroradiology. 1997;39(1):19–22.
    OpenUrlCrossRefPubMed
  27. 27.↵
    Thomson AD. Mechanisms of vitamin deficiency in chronic alcohol misusers and the development of the Wernicke-Korsakoff syndrome. Alcohol and Alcoholism. 2000;35(Supplement_1):2–1.
    OpenUrlCrossRef
  28. 28.↵
    Vatsalya V, Song M, Schwandt ML, et al. Effects of sex, drinking history, and omega-3 and omega-6 fatty acids dysregulation on the onset of liver injury in very heavy drinking alcohol-dependent patients. Alcoholism: Clinical and Experimental Research. 2016;40(10):2085–2093.
    OpenUrl
  29. 29.
    Vatsalya V, Kong M, Cave MC, et al. Association of serum zinc with markers of liver injury in very heavy drinking alcohol-dependent patients. The Journal of nutritional biochemistry. 2018;59:49–55.
    OpenUrl
  30. 30.
    Vatsalya V, Agrawal R, Frimodig J, Srivastava S, Schwandt ML. Dysregulation in Plasma ω3 Fatty Acids Concentration and Serum Zinc in Heavy Alcohol-Drinking HCV Patients. Advances in Virology. 2020;2020.
  31. 31.↵
    Vatsalya V, Cave MC, Kong M, et al. Keratin 18 is a diagnostic and prognostic factor for acute alcoholic hepatitis. Clinical Gastroenterology and Hepatology. 2019.
  32. 32.↵
    Smithline HA, Donnino M, Greenblatt DJ. Pharmacokinetics of high-dose oral thiamine hydrochloride in healthy subjects. BMC clinical pharmacology. 2012;12(1):4.
    OpenUrl
  33. 33.↵
    Mandel H, Berant M, Hazani A, Naveh Y. Thiamine-dependent beriberi in the thiamine-responsive anemia syndrome. New England Journal of Medicine. 1984;311(13):836–838.
    OpenUrlCrossRefPubMedWeb of Science
  34. 34.↵
    Riaz S, Skinner V, Srai SK. Effect of high dose thiamine on the levels of urinary protein biomarkers in diabetes mellitus type 2. Journal of pharmaceutical and biomedical analysis. 2011;54(4):817–825.
    OpenUrlPubMed
  35. 35.↵
    Moskowitz A, Andersen LW, Cocchi MN, Karlsson M, Patel PV, Donnino MW. Thiamine as a Renal Protective Agent in Septic Shock. A Secondary Analysis of a Randomized, Double-Blind, Placebo-controlled Trial. Ann Am Thorac Soc. 2017;14(5):737–741.
    OpenUrlCrossRefPubMed
  36. 36.↵
    Marik PE, Khangoora V, Rivera R, Hooper MH, Catravas J. Hydrocortisone, vitamin C, and thiamine for the treatment of severe sepsis and septic shock: a retrospective before-after study. Chest. 2017;151(6):1229–1238.
    OpenUrlCrossRefPubMed
  37. 37.↵
    Mouly S. Beri-Beri and thiamine deficiency in HIV infection. Aids. 1996;10(8):931.
    OpenUrlCrossRefPubMedWeb of Science
  38. 38.
    Arici C, Tebaldi A, Quinzan G, Maggiolo F, Ripamonti D, Suter F. Severe lactic acidosis and thiamine administration in an HIV-infected patient on HAART. International journal of STD & AIDS. 2001;12(6):407–409.
    OpenUrl
  39. 39.↵
    Margolis AM, Heverling H, Pham PA, Stolbach A. A review of the toxicity of HIV medications. Journal of Medical Toxicology. 2014;10(1):26–39.
    OpenUrl
  40. 40.↵
    Di Rocco M, Lamba LD, Minniti G, Caruso U, Naito E. Outcome of thiamine treatment in a child with Leigh disease due to thiamine-responsive pyruvate dehydrogenase deficiency. European Journal of Paediatric Neurology. 2000;4(3):115–117.
    OpenUrl
  41. 41.↵
    Day E, Bentham PW, Callaghan R, Kuruvilla T, George S. Thiamine for prevention and treatment of Wernicke-Korsakoff Syndrome in people who abuse alcohol. Cochrane Database of Systematic Reviews. 2013(7).
  42. 42.↵
    Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet. 2020;395(10223):497–506.
    OpenUrlCrossRefPubMed
  43. 43.
    Wu D, Yang XO. TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib. Journal of Microbiology, Immunology and Infection. 2020.
  44. 44.↵
    Liu Y, Zhang C, Huang F, et al. Elevated plasma level of selective cytokines in COVID-19 patients reflect viral load and lung injury. National Science Review. 2020.
  45. 45.↵
    Pirowska M, Obtułowicz A, Lipko-Godlewska S, Goździalska A, Podolec K, Wojas-Pelc A. The level of proinflammatory cytokines: interleukins 12, 23, 17 and tumor necrosis factor α in patients with metabolic syndrome accompanying severe psoriasis and psoriatic arthritis. Advances in Dermatology and Allergology/Postȩpy Dermatologii i Alergologii. 2018;35(4):360.
    OpenUrl
  46. 46.↵
    Kotake S, Udagawa N, Takahashi N, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. The Journal of clinical investigation. 1999;103(9):1345–1352.
    OpenUrlCrossRefPubMedWeb of Science
  47. 47.↵
    Brunialti MKC, Santos MC, Rigato O, Machado FR, Silva E, Salomao R. Increased percentages of T helper cells producing IL-17 and monocytes expressing markers of alternative activation in patients with sepsis. PloS one. 2012;7(5):e37393.
    OpenUrlCrossRefPubMed
  48. 48.↵
    Li J, Li M, Su L, et al. Alterations of T helper lymphocyte subpopulations in sepsis, severe sepsis, and septic shock: a prospective observational study. Inflammation. 2015;38(3):995–1002.
    OpenUrlCrossRefPubMed
  49. 49.↵
    Crowe CR, Chen K, Pociask DA, et al. Critical role of IL-17RA in immunopathology of influenza infection. The Journal of Immunology. 2009;183(8):5301–5310.
    OpenUrl
  50. 50.↵
    Qu N, Xu M, Mizoguchi I, et al. Pivotal roles of T-helper 17-related cytokines, IL-17, IL-22, and IL-23, in inflammatory diseases. Clinical and Developmental Immunology. 2013;2013.
  51. 51.↵
    Mao L, Wang M, Chen S, et al. Neurological manifestations of hospitalized patients with COVID-19 in Wuhan, China: a retrospective case series study. 2020.
  52. 52.↵
    Hotez PJ, Bottazzi ME, Corry DB. The potential role of TH17 immune responses in coronavirus immunopathology and vaccine-induced immune enhancement. In: Elsevier; 2020.
  53. 53.↵
    Song X, Qian Y. IL-17 family cytokines mediated signaling in the pathogenesis of inflammatory diseases. Cell Signal. 2013;25(12):2335–2347.
    OpenUrlCrossRefPubMed
  54. 54.↵
    Veldhoen M. Interleukin 17 is a chief orchestrator of immunity. Nat Immunol. 2017;18(6):612–621.
    OpenUrlCrossRef
  55. 55.↵
    Lasiglie D, Traggiai E, Federici S, et al. Role of IL-1 Beta in the Development of Human TH 17 Cells: Lesson from NLPR3 Mutated Patients. PloS one. 2011;6(5):e20014.
    OpenUrlCrossRefPubMed
  56. 56.↵
    Gu Y, Yang J, Ouyang X, et al. Interleukin 10 suppresses Th17 cytokines secreted by macrophages and T cells. European journal of immunology. 2008;38(7):1807–1813.
    OpenUrlCrossRefPubMedWeb of Science
  57. 57.↵
    Ji Z, Fan Z, Zhang Y, et al. Thiamine deficiency promotes T cell infiltration in experimental autoimmune encephalomyelitis: the involvement of CCL2. The Journal of Immunology. 2014;193(5):2157–2167.
    OpenUrl
  58. 58.↵
    Mebratu YA, Tesfaigzi Y. IL-17 Plays a Role in Respiratory Syncytial Virus-induced Lung Inflammation and Emphysema in Elastase and LPS-injured Mice. Am J Respir Cell Mol Biol. 2018;58(6):717–726.
    OpenUrl
  59. 59.↵
    Murdock BJ, Falkowski NR, Shreiner AB, et al. Interleukin-17 drives pulmonary eosinophilia following repeated exposure to Aspergillus fumigatus conidia. Infection and immunity. 2012;80(4):1424–1436.
    OpenUrlAbstract/FREE Full Text
  60. 60.↵
    Shoji S, Furuishi K, Misumi S, Miyazaki T, Kino M, Yamataka K. Thiamine disulfide as a potent inhibitor of human immunodeficiency virus (type-1) production. Biochemical and biophysical research communications. 1994;205(1):967–975.
    OpenUrlPubMed
  61. 61.↵
    Butterworth RF, Gaudreau C, Vincelette J, Bourgault A-M, Lamothe F, Nutini A-M. Thiamine deficiency and Wernicke’s encephalopathy in AIDS. Metabolic brain disease. 1991;6(4):207–212.
    OpenUrlCrossRefPubMedWeb of Science
  62. 62.↵
    Wallace AE, Weeks WB. Thiamine treatment of chronic hepatitis B infection. The American journal of gastroenterology. 2001;96(3):864–868.
    OpenUrlCrossRefPubMedWeb of Science
  63. 63.↵
    Kim W-Y, Jo E-J, Eom JS, et al. Combined vitamin C, hydrocortisone, and thiamine therapy for patients with severe pneumonia who were admitted to the intensive care unit: Propensity score-based analysis of a before-after cohort study. Journal of critical care. 2018;47:211–218.
    OpenUrl
  64. 64.↵
    Coates PM, Betz JM, Blackman MR, et al. Encyclopedia of dietary supplements. CRC Press; 2010.
  65. 65.↵
    Boldorini R, Vago L, Lechi A, Tedeschi F, Trabattoni G. Wernicke’s encephalopathy: occurrence and pathological aspects in a series of 400 AIDS patients. Acta Bio-medica de L’ateneo Parmense: Organo Della Societa di Medicina e Scienze Naturali di Parma. 1992;63(1–2):43–49.
    OpenUrl
  66. 66.↵
    Larsen TR, Dragu D, Williams M. Wernicke’s encephalopathy: an unusual consequence of the acquired immune deficiency syndrome—case report and literature review. Case reports in medicine. 2013;2013.
  67. 67.↵
    Mendoza R, Anderson MM, Overbaugh J. A putative thiamine transport protein is a receptor for feline leukemia virus subgroup A. Journal of Virology. 2006;80(7):3378–3385.
    OpenUrlAbstract/FREE Full Text
  68. 68.↵
    Plaut G. Water-soluble vitamins, part II (folic acid, riboflavin, thiamine, vitamin B12). Annual Review of Biochemistry. 1961;30(1):409–444.
    OpenUrlWeb of Science
  69. 69.
    Wang H-Y, Li X-L, Yan Z-R, Sun X-P, Han J, Zhang B-W. Potential neurological symptoms of COVID-19. Therapeutic Advances in Neurological Disorders. 2020;13:1756286420917830.
  70. 70.
    Chaudhuri A, Kennedy P. Diagnosis and treatment of viral encephalitis. Postgraduate medical journal. 2002;78(924):575–583.
    OpenUrlAbstract/FREE Full Text
  71. 71.
    Sechi G, Serra A. Wernicke’s encephalopathy: new clinical settings and recent advances in diagnosis and management. The Lancet Neurology. 2007;6(5):442–455.
    OpenUrl
  72. 72.
    Reuler JB, Girard DE, Cooney TG. Wernicke’s encephalopathy. New England Journal of Medicine. 1985;312(16):1035–1039.
    OpenUrlCrossRefPubMedWeb of Science
  73. 73.
    Wu P, Duan F, Luo C, et al. Characteristics of ocular findings of patients with coronavirus disease 2019 (COVID-19) in Hubei Province, China. JAMA ophthalmology. 2020;138(5):575–578.
    OpenUrl
  74. 74.
    Lantos J, Strauss S, Lin E. COVID-19–Associated Miller Fisher Syndrome: MRI Findings. American Journal of Neuroradiology. 2020.
  75. 75.
    Keane JR. Bilateral ocular paralysis: analysis of 31 inpatients. Archives of neurology. 2007;64(2):178–180.
    OpenUrlCrossRefPubMed
  76. 76.
    Keane JR. Internuclear ophthalmoplegia: unusual causes in 114 of 410 patients. Archives of neurology. 2005;62(5):714–717.
    OpenUrlCrossRefPubMedWeb of Science
  77. 77.
    Hedges III TR. Ophthalmoplegia associated with AIDS. Survey of ophthalmology. 1994;39(1):43–51.
    OpenUrlPubMed
  78. 78.
    Sanjay S, Chan EWe, Gopal L, Hegde SR, Chang BC-M. Complete unilateral ophthalmoplegia in herpes zoster ophthalmicus. Journal of Neuro-ophthalmology. 2009;29(4):325–337.
    OpenUrlCrossRefPubMed
  79. 79.
    Yeh EA, Collins A, Cohen ME, Duffner PK, Faden H. Detection of coronavirus in the central nervous system of a child with acute disseminated encephalomyelitis. Pediatrics. 2004;113(1):e73–e76.
    OpenUrlAbstract/FREE Full Text
  80. 80.
    Whitley RJ, Gnann JW. Viral encephalitis: familiar infections and emerging pathogens. The Lancet. 2002;359(9305):507–513.
    OpenUrl
  81. 81.
    Kabakus N, Gurgoze MK, Yildirim H, Godekmerdan A, Aydın M. Acute hemorrhagic leukoencephalitis manifesting as intracerebral hemorrhage associated with herpes simplex virus type I. Journal of tropical pediatrics. 2005;51(4):245–249.
    OpenUrlCrossRefPubMed
  82. 82.
    Kumar G, Kalita J, Misra UK. Raised intracranial pressure in acute viral encephalitis. Clinical neurology and neurosurgery. 2009;111(5):399–406.
    OpenUrlCrossRefPubMed
  83. 83.
    Hao X, Zhou D, Li Z, et al. Severe psychological distress among patients with epilepsy during the COVID-19 outbreak in southwest China. Epilepsia. 2020.
  84. 84.
    Misra UK, Tan CT, Kalita J. Viral encephalitis and epilepsy. Epilepsia. 2008;49:13–18.
    OpenUrlCrossRef
  85. 85.
    Aguilar MJ, Rasmussen T. Role of encephalitis in pathogenesis of epilepsy. AMA Archives of Neurology. 1960;2(6):663–676.
    OpenUrl
  86. 86.
    Nguyen TA, Lam SW. Phenobarbital and symptom-triggered lorazepam versus lorazepam alone for severe alcohol withdrawal in the intensive care unit. Alcohol. 2020;82:23–27.
    OpenUrl
  87. 87.
    Steardo L, Steardo Jr L, Zorec R, Verkhratsky A. Neuroinfection may contribute to pathophysiology and clinical manifestations of COVID-19. Acta Physiologica. 2020:e13473.
  88. 88.
    Reichard RR, Kashani KB, Boire NA, Constantopoulos E, Guo Y, Lucchinetti CF. Neuropathology of COVID-19: a spectrum of vascular and acute disseminated encephalomyelitis (ADEM)-like pathology. Acta Neuropathologica. 2020:1–6.
  89. 89.
    Dale RC. Acute disseminated encephalomyelitis. Paper presented at: Seminars in pediatric infectious diseases2003.
  90. 90.
    Whitley RJ. Viral encephalitis. New England Journal of Medicine. 1990;323(4):242–250.
    OpenUrlCrossRefPubMedWeb of Science
  91. 91.
    Rao R, Topiwala A. Alcohol use disorders and the brain. Addiction. 2020.
  92. 92.
    Gautier JF, Ravussin Y. A New Symptom of COVID-19: Loss of Taste and Smell. Obesity. 2020;28(5):848–848.
    OpenUrl
  93. 93.
    Lechien JR, Chiesa-Estomba CM, De Siati DR, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. European Archives of Oto-Rhino-Laryngology. 2020:1–11.
  94. 94.
    Finsterer J, Stollberger C. Causes of hypogeusia/hyposmia in SARS-CoV2 infected patients. Journal of Medical Virology. 2020.
  95. 95.
    Henkin R, Larson A, Powell R. Hypogeusia, dysgeusia, hyposmia, and dysosmia following influenza-like infection. Annals of Otology, Rhinology & Laryngology. 1975;84(5):672–682.
    OpenUrl
  96. 96.
    Bénézit F, Le Turnier P, Declerck C, et al. Utility of hyposmia and hypogeusia for the diagnosis of COVID-19. The Lancet Infectious Diseases. 2020.
  97. 97.
    Azhideh A. COVID-19 Neurological Manifestations. International Clinical Neuroscience Journal. 2020;7(2):54.
    OpenUrl
  98. 98.
    Tang H, Falcone F, Eljamel S. Herpes simplex encephalitis following microvascular decompression for trigeminal neuralgia: Case report. Journal of Neurosurgery. 2013;118(3):530–533.
    OpenUrl
  99. 99.
    Johnson RW, Bouhassira D, Kassianos G, Leplège A, Schmader KE, Weinke T. The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC medicine. 2010;8(1):37.
    OpenUrl
  100. 100.
    Rose AS, Jacobson BM. Treatment of trigeminal neuralgia with vitamin B1 (thiamine hydrochloride). Archives of Neurology & Psychiatry. 1940;44(6):1307–1311.
    OpenUrl
  101. 101.
    Eckert M, Schejbal P. Therapy of neuropathies with a vitamin B combination. Symptomatic treatment of painful diseases of the peripheral nervous system with a combination preparation of thiamine, pyridoxine and cyanocobalamin. Fortschritte der Medizin. 1992;110(29):544–548.
    OpenUrlPubMed
  102. 102.
    He J, Wu B, Chen Y, et al. Characteristic ECG manifestations in patients with COVID-19. Canadian Journal of Cardiology. 2020.
  103. 103.
    Kochi AN, Tagliari AP, Forleo GB, Fassini GM, Tondo C. Cardiac and arrhythmic complications in patients with COVID-19. Journal of Cardiovascular Electrophysiology. 2020;31(5):1003–1008.
    OpenUrlPubMed
  104. 104.
    Chua KB, Goh KJ, Wong KT, et al. Fatal encephalitis due to Nipah virus among pig-farmers in Malaysia. The Lancet. 1999;354(9186):1257–1259.
    OpenUrl
  105. 105.
    Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, evaluation and treatment coronavirus (COVID-19). In: Statpearls [internet]. StatPearls Publishing; 2020.
  106. 106.
    Ripamonti E, Gaffuri M, Molteni F. Cognitive, neuropsychiatric, and motor profile in post tick-borne flaviviral encephalomyelitis. Neurological Sciences. 2020.
  107. 107.
    Pitel A-L, Zahr NM, Jackson K, et al. Signs of preclinical Wernicke’s encephalopathy and thiamine levels as predictors of neuropsychological deficits in alcoholism without Korsakoff’s syndrome. Neuropsychopharmacology. 2011;36(3):580–588.
    OpenUrlCrossRefPubMedWeb of Science
  108. 108.
    Nardone R, Bergmann J, Kronbichler M, et al. Altered motor cortex excitability to magnetic stimulation in alcohol withdrawal syndrome. Alcoholism: clinical and experimental research. 2010;34(4):628–632.
    OpenUrlPubMed
  109. 109.
    Blass JP, Gibson GE. Abnormality of a thiamine-requiring enzyme in patients with Wernicke-Korsakoff syndrome. New England Journal of Medicine. 1977;297(25):1367–1370.
    OpenUrlCrossRefPubMedWeb of Science
  110. 110.
    Mori M, Kuwabara S, Fukutake T, Yuki N, Hattori T. Clinical features and prognosis of Miller Fisher syndrome. Neurology. 2001;56(8):1104–1106.
    OpenUrlCrossRefPubMed
Back to top
Posted August 25, 2020.
Download PDF

Supplementary Material

Data/Code
Email
Therapeutic Prospects for Th-17 Cell Immune Storm Syndrome and Neurological Symptoms in COVID-19: Thiamine Efficacy and Safety, In-vitro Evidence and Pharmacokinetic Profile
Vatsalya Vatsalya, Fengyuan Li, Jane Frimodig, Khushboo S. Gala, Shweta Srivastava, Maiying Kong, Vijay A Ramchandani, Wenke Feng, Xiang Zhang, Craig J McClain
medRxiv 2020.08.23.20177501; doi: https://doi.org/10.1101/2020.08.23.20177501
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area